Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07569328
NA

Low-dose Colchicine for CABG Graft Failure Prevention

Sponsor: Beijing Anzhen Hospital

View on ClinicalTrials.gov

Summary

This study aims to evaluate whether daily low-dose colchicine (0.5 mg), administered in addition to the standard secondary prevention regimen recommended in clinical guidelines after coronary artery bypass grafting (CABG), can further prevent graft failure after CABG through a prospective, randomized, double-blind, placebo-controlled clinical trial.

Official title: Low-dose Colchicine for CABG Graft Failure Prevention: A Randomized, Double-Blind, Placebo-Controlled Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

622

Start Date

2026-09-01

Completion Date

2029-09-01

Last Updated

2026-05-06

Healthy Volunteers

No

Interventions

DRUG

Colchicine Pill

Colchicine 0.5 mg once daily will be given on the basis of guideline-recommended standard secondary prevention therapy after CABG for 24 months.

DRUG

Placebo

Placebo one tablet once daily will be given on the basis of guideline-recommended standard secondary prevention therapy after CABG for 24 months.

Locations (1)

Beijing Anzhen Hospital

Beijing, Beijing Municipality, China